

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C12N 15/67, 15/81	A2	(11) International Publication Number: WO 94/19472 (43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/GB94/00373 (22) International Filing Date: 25 February 1994 (25.02.94) (30) Priority Data: 9303988.1 26 February 1993 (26.02.93) GB (71) Applicant (for all designated States except US): THE PUBLIC HEALTH LABORATORY SERVICE BOARD [GB/GB]; 61 Colindale Avenue, London NW9 5DF (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): MINTON, Nigel, Peter [GB/GB]; 27 Moberly Road, Salisbury, Wiltshire SP1 3BZ (GB). FAULKNER, James, Duncan, Bruce [GB/GB]; 14 Bishops Court, John Garne Way, Marston, Oxford, Oxfordshire OX3 0TX (GB). (74) Agent: LOCKWOOD, Peter, Brian; MOD(PE), DIPR, IPR1b, Room 2002 Empress State Building, Lillie Road, London SW6 1TR (GB).		(81) Designated States: AU, CA, GB, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: BI-FUNCTIONAL EXPRESSION SYSTEM (57) Abstract A novel expression system is provided comprising a DNA sequence containing transcriptional and translational signals that promote the over production of recombinant proteins both in bacterial hosts (e.g., <i>Escherichia coli</i>) and yeasts (e.g., <i>Saccharomyces cerevisiae</i>). The design of the expression system lends itself to a unique strategy which allows heterologous genes to be directly cloned at a position relative to the transcription/translation signals which is optimal for expression. Particularly provided are expression cassettes comprising a sequence of the invention combined with a purpose built series of plasmids wherein the utility and efficiency of the resultant expression vectors can be demonstrated to over produce protein, particularly phenylalanine ammonia lyase (herein abbreviated to PAL), in <i>E. coli</i> and <i>S. cerevisiae</i> to levels hitherto unattainable.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BI-FUNCTIONAL EXPRESSION SYSTEM.

The present invention relates to novel promoter DNA, particularly a novel expression system comprising DNA having a sequence containing transcriptional and translational signals that promote the over production of recombinant proteins both in bacterial hosts (eg., Escherichia coli) and yeasts (eg., Saccharomyces cerevisiae); and to a novel cloning method that allows the insertion of a heterologous gene into a vector or expression cassette directly at the authentic translational start point of a promoter, with no deleterious changes being made to either the native 5'-UTR of a vector promoter or to the codons of the inserted gene; allowing production of that promoter DNA. The design of the expression system lends itself to this unique strategy which allows heterologous genes to be directly cloned at a optimal position relative to the transcription /translation signals.

Particularly provided are expression cassettes comprising a sequence of the invention combined with a purpose built series of plasmids wherein the utility and efficiency of the resultant expression vectors can be demonstrated to over produce protein, particularly that of phenylalanine ammonia lyase (herein abbreviated to PAL), in E. coli and S. cerevisiae to levels hitherto unattainable.

Although considerable progress has been made towards the development of expression systems for yeast (reviewed in Rose and Broach, 1990), the vectors lack the sophistication and versatility of their bacterial counterparts. Current vectors often contain many superfluous DNA sequences, which make them cumbersome and difficult to amplify and isolate in large quantities. The wealth of DNA present means that unique restriction sites are limited in number.

Yeast expression vectors are usually of the "sandwich" variety, whereby cloning sites are "sandwiched" between a homologous yeast promoter and transcriptional termination signals. The precise positioning of the cloning sites with respect to the authentic initiating codon (AUG) of the homologous yeast promoter represents something of a dilemma. If one chooses to place the cloning sites upstream to the AUG, then one inevitably disrupts the native 5'-untranslated region (5'-UTR) of the yeast promoter. Unavoidable

insertion of heterologous untranslated sequence elements containing a high proportion of G residues, or elements creating secondary structures or containing the inserted AUG in a sub-optimal nucleotide context, can have catastrophic effects on expression levels, regardless of the strength of transcriptional activation signals (Donahue and Cigan, 1988; Baim and Sherman, 1988). For example, Bitter and Egan (1984) reported 10 - 15 fold lower expression levels of a Hepatitis B surface antigen (HBsAg) gene, fused to a yeast glyceraldehyde-3-phosphate (GPD) gene promoter, but utilising the native HBsAg 5' flanking region, compared to HBsAg fused to a GPD promoter and utilising the GPD 5' flanking region.

The alternative is to position the cloning sites immediately 3' to the authentic AUG of the yeast promoter. However, this has its own concomitant problems. Care must be taken that the fusion is "in frame", while the non-authentic amino terminus of the expressed protein may have unpredictable effects on its biological activity and antigenicity. These last two points render such fusion proteins unsuitable for use as a pharmaceutical without modification.

Preferably cloning is directly from the authentic AUG initiation codon. However, there has been no reported instance of a native yeast promoter with a usable restriction site encompassing its translational start point and the artificial creation of one would inevitably disrupt the start codon or its nucleotide context. The alternative is the lengthy and expensive procedure of chemically synthesizing an oligonucleotide "bridge" fragment that reaches from a convenient restriction site in the promoter 5' to the translational start to a site 3' to the ATG in the coding region to be expressed. Such a procedure is not applicable to a routine, versatile cloning strategy.

A further disadvantage with currently available yeast expression vectors is that as they employ homologous yeast promoters containing powerful transcriptional activating sequences and they do not direct the efficient transcription or translation in bacterial hosts, such as E. coli (Ratzkin and Carbon, 1977; Struhl, 1986). Similarly, bacterial derived transcriptional/translational signals are inefficiently utilised in S. cerevisiae, if at all. Comparative expression studies of heterologous genes in E. coli and S. cerevisiae

therefore require the use of two separate vector systems.

A preferred aspect of the present invention describes how both the specificity and efficiency of a yeast promoter element, particularly that of S. cerevisiae, particularly that of PGK, can be changed to direct the high expression of heterologous genes in bacteria and yeasts.

A first aspect of the invention provides promoter DNA incorporating a structural gene starting position characterised in that the DNA has a unique SspI restriction site at the structural gene start position. A second aspect of the invention provides a novel cloning strategy ie. method, that allows the insertion of a heterologous gene into the expression cassette directly at the authentic translational start point of the promoter, with no deleterious changes being made to either the native 5'-UTR of the vector promoter or to the codons of the inserted gene; thus providing the promoter DNA of the first aspect.

A third aspect of the invention provides recombinant DNA comprising a yeast promoter sequence, particularly of S. cerevisiae, characterized in that the leader region of the promoter sequence is replaced with that of the replication protein 2 (REP2) gene (ORF C) of the yeast 2 μ m plasmid (Hartley and Donelson, 1980). A preferred yeast promoter derived portion is that of the phosphoglycerate kinase (PGK) promoter and encompasses powerful upstream activating sequences (UAS) (Ogden et al., 1986), responsible for efficient transcription in S. cerevisiae. The sequences necessary for efficient transcription in E. coli reside in the REP2 derived portion of the hybrid promoter. Sequences necessary for efficient translation, both in S. cerevisiae and E. coli, also reside in the REP2-derived portion of the promoter.

A fourth aspect of the invention provides the promoter hybrid of the invention incorporated into an expression "cassette", in which a copy of the lacZ' gene, containing the multiple cloning sites of pMTL23, is preceded by the promoter, and followed by tandemly arranged, yeast gene-derived, transcriptional terminators.

In the cloning method of the second aspect (illustrated in Figure 1) promoter DNA incorporating a structural gene starting position eg. within an expression cassette, is modified using SDM by creating a

unique SspI restriction site at a structural gene start position. The position of this created site is such that the triplet sequence, ATG, corresponding to the translational start codon of the structural gene becomes ATA within the SspI recognition site AATATT. The heterologous gene to be inserted is similarly modified. In this case the nucleotide triplet corresponding to the translational start codon (eg., AUG, GUG, or UUG) is changed to CAG, while the triplet immediately 5' is changed to CTG. These changes correspond to the creation of a PstI restriction site, CTGCAG. The creation of the PstI, or equivalent site, can be conveniently performed simultaneously to isolation of the gene by utilising a mutagenic primer in a polymerase chain reaction (PCR) catalysed gene amplification procedure (Higuchi et al., 1988). The modified heterologous gene can be then digested with PstI restriction endonuclease and the 3' overhanging ends removed eg. by the 3' to 5' exo-nucleolytic activity of T4 DNA polymerase. The heterologous gene can then be excised using any of the restriction enzymes whose sites are present within the polylinker of the vector.

The net result of the actions of these DNA modifying enzymes is that the first base of the blunt-ended DNA fragment is the third nucleotide, "G", of its first codon. It is then ligated into the vector which has been digested previously with SspI and a restriction enzyme compatible with that used to excise the heterologous gene. Fusion of the vector promoter region (which ends in "AT") and heterologous gene (which begins in a "G") results in the recreation of the translational start, ATG.

The fourth aspect of the invention provides an expression system obtainable using the method of the invention such that overexpression of proteins is possible. A particular example of this is provided in the over expression of phenylalanine ammonia-lyase (PAL) gene from Rhodospiridium toruloides in both E. coli and S. cerevisiae. This is made possible by incorporating an expression cassette provided by the method into a purpose built, unique series of S.cerevisiae/ E. coli shuttle plasmids. Preferably every component of these shuttle plasmids is extensively modified to reduce the presence of superfluous DNA in the final vectors and to eliminate nucleotide sequence motifs corresponding to the restriction enzyme recognition sites of use in

the operation of the expression cassette. The levels of recombinant PAL attained in *S. cerevisiae* are significantly higher than that obtained using the PGK promoter alone. Whereas the PGK promoter alone fails to elicit the expression of PAL in *E. coli*, the levels of recombinant PAL obtained using the hybrid promoters are far in excess of those previously obtained using expression vectors designed for high expression in *E. coli*.

The DNA, cassettes, and organisms of the present invention will now be illustrated by reference to the following non-limiting Figures and Examples. Other variations falling within the scope of the invention will be apparent to those skilled in the art in the light of these.

FIGURES and SEQUENCE LISTING SEQUENCES:

Figure 1: shows the design of the novel cloning method which allows cloning to take place directly at the authentic translational start point of a promoter.

Figure 2: shows a comparison of sequences found 5' to the translational start codon in REP2 and PGK, compared to a consensus yeast sequence, the sequence found 5' to the neo gene and a consensus procaryotic promoter sequence.

Figure 3: shows how genes are inserted into the expression cassette using the SspI site.

Figure 4: shows an overview of the pMTL 8XXX vectors of the invention.

Figure 5: shows an SDS-PAGE electrophoretogram of lysates derived from microbial cells producing recombinant PAL.

Figure 6: shows the construction of pMTL 8000 and pMTL 8100 by inserting a 1.4 kb RsaI fragment from pVT100-U, containing the origin of replication and the STB locus from the 2 μ m circle plasmid, into the EcoRV site of pMTLJ and pMTL CJ.

Figure 7: shows the construction of pMTLCJ by replacing the bla gene of pMTL4 with the cat gene of pCM4, modified by SDM-mediated removal of EcoRI, NcoI and SspI restriction sites.

SEQ ID No 1: shows the complete nucleotide sequence of a novel expression cassette (SEQ ID No 1) of the invention including a sequence comprising the PGK::REP2 promoter (bases 1-635; REP2 fragment consists of bases 547-635 of SEQ ID No 1).

SEQ ID No 2: is the complete nucleotide sequence of a comparative control cassette, containing the PGK promoter.

SEQ ID No 3: is the nucleotide sequence of plasmid pMTL8000.

SEQ ID No 4: is the nucleotide sequence of plasmid pMTL8100.

SEQ ID No 5: is the nucleotide sequence of the URA3-J and ura3-dJ (189 =G) alleles used in the vector construction.

SEQ ID No 6: is the nucleotide sequence of the leu2-dJ allele used in vector construction.

In SEQ ID No 1, the original nucleotide source DNA sequences have been changed by SDM at the following points:

Base 548-549	was TT	now AC	Creates ClaI::AccI
Base 557	was G	now T	
Base 580	was G	now T	
Base 636-638	was GTG	now ATT	
Base 1033-1035	was TAA	now GTT	Creates HpaI::BglII
Base 1149	was G	now C	Removes ClaI
Base 1223	was T	now A	Removes SspI
Base 1484	was G	now T	Removes AccI

Restriction endonuclease sites are provided in regions of DNA as follows:

Base 630-640 SspI
 Base 760-870 NruI, StuI, XhoI, BglII, ClaI, SphI, NcoI, KpnI, SmaI, SstI, EcoRI, XbaI, HindIII, PstI, MluI, AccI, SalI, AatII, NdeI, BamHI, EcoRV, NaeI.
 Base 1610-1619 SphI

Fusible ends were produced from the source DNA by ClaI and AccI for the fusion between base 546 and 547; by HpaI and BglII at for the fusion between base 1035 and 1036 and by HindIII and HincII for the fusion between base 1412 and 1413.

In SEQ ID No 2, the original nucleotide source DNA sequences have been changed by SDM at the following points:

Base 3	was C	now A	Creates EcoRI
Base 725-727	was GAT	now AAG	Removes ClaI
Base 768-770	was GTC	now ATT	Creates SspI
Base 1165-1167	was TAA	now GTT	Creates HpaI
Base 1281	was G	now C	Removes ClaI
Base 1356	was T	now A	Removes SspI
Base 1616	was G	now T	Removes AccI

Restriction endonuclease sites are provided in regions of DNA as follows:

Base 1-10 EcoRI
Base 180-190 XmnI
Base 760-770 SspI
Base 890-1000 NruI, StuI, XhoI, BglII, ClaI, SphI, NcoI, KpnI, SmaI, SstI, EcoRI, XbaI, HindIII, PstI, MluI, AccI, SalI, AatII, NdeI, BamHI, EcoRV, NaeI.
Base 1740-1751 SphI

Fusible ends were produced from the source DNA using HpaI and BglII for the fusion between 1167 and 1168; and using HindIII::HincII for the fusion between 1543 and 1544.

In SEQ ID No 3 derived from pVT100-U (bases 1-290 and 2295-3400) and pMTLJ (bases 291-2294), the original nucleotide source DNA sequences have been changed at the following points:

Base 425	was T	now C	Removes SspI
----------	-------	-------	--------------

Restriction endonuclease sites are provided in regions of DNA as follows:

Base 1-10 SspI
 Base 1360-1370 DraI
 Base 2520-2530 HpaI

Fusable ends were produced from the source DNA using RsaI::EcoRV for the fusion between bases 290 and 291 and using EcoRV::RsaI for the fusion between bases 2294 and 2294.

In SEQ ID No 4 derived from pVT100-U (bases 1-290 and 1244-3249), pMTL4/CJ (bases 291-426 and 1214-2143) and pCM4 (bases 427-1213), the original nucleotide source sequences have been changed at the following points:

Base 676	was A	now G	Removes EcoRI
Base 976	was C	now A	Removes NcoI
Base 985	was A	now G	Removes SspI

Restriction endonuclease sites are provided in regions of DNA as follows:

Base 1-10 SspI
 Base 2370-2380 HpaI

Fusable ends were produced from the using RsaI::EcoRV for the fusion between bases 290 and 291, SspI::BamHI for the fusion between bases 426 and 427, BamHI::DraI for the fusion between bases 1213 and 1214 and EcoRV::RsaI for the fusion between bases 2143 and 2144.

In SEQ ID No 5 the original nucleotide source sequence has been changed at the following points:

Base 150	was C	now G	Removes NdeI
Base 289	was G	now C	Removes HpaI
Base 440	was C	now G	Removes NcoI
Base 563	was C	now T	Removes StuI
Base 1063	was G	now C	Removes AccI

Restriction endonuclease sites are thus absent from this sequence.

In SEQ ID No 6 the original nucleotide source sequence has been changed at the following points:

Base 294	was T	now C	Removes ClaI
Base 780	was C	now T	Removes EcoRI

Restriction endonuclease sites are provided in regions of DNA as follows:

Base 380-390 KpnI

Example 1: Expression Cassettes. An example nucleotide composition of the expression cassette containing the essential elements of this invention is designated SEQ ID 1, and was formed by fusing DNA regions from PGK (base 1-546 and base 1036-1411), REP2 (base 547-635), lacZ' (base 636-1035) and ADH1 (base 1412-1619); base numbers are those in SEQ ID No 1 not source DNA. Prior to fusion, the sequence composition of each element was altered to varying extents using site-directed mutagenesis (SDM). In the majority of cases the changes were made either to eliminate a restriction enzyme recognition common to the polylinker region within lacZ', or to create a restriction recognition site to facilitate the construction of the cassette. To compare the advantages of the novel promoter element, a second cassette was constructed, which contained no REP2 derived nucleotides, to act as a control. The sequence composition of this control cassette is shown as SEQ ID No 2.

The expression cassettes consist of the E. coli lacZ' gene, containing the pMTL23 polylinker cloning sites (Chambers et al., 1988), sandwiched by nucleotide signals for transcriptional initiation and termination. The transcriptional initiation signals of the hybrid promoter are provided by a unique combination of sequences derived from the promoters of PGK and REP2. The upstream activating sequence (UAS) element and TATA-box are from the PGK promoter and are fused to the 86 nucleotides residing immediately 5' to the 2 μ m plasmid REP2 gene. The REP2 promoter is constitutive in nature (Som et al., 1988), and not generally regarded as a "strong" yeast promoter.

Within the hybrid promoter, the REP2 region is also responsible for

providing the expression cassette with promoter activity in *E. coli*. The region used contains sequence motifs which exactly correspond to those sequences necessary for transcription in procaryotes such as *E. coli*. Thus two hexanucleotide sequences are present, TTGACA and TATAAT, which exactly correspond to the consensus -35 and -10 boxes of *E. coli* promoters (Harley and Reynolds, 1987), and the spacing between them, 18 bp, is also consistent with a functional *E. coli* promoter. In addition, the AUG start codon of REP2 is preceded by the nucleotide motif -AGAA-.

The transcription initiation and termination signals flank unique restriction enzyme recognition sites into which heterologous genes may be inserted; with the exception of SspI, these sites form part of the lacZ' structural gene. Their location within the lacZ' gene allows the rapid detection of recombinant clones derived from the plasmid. The lacZ' gene encodes the alpha-peptide of β -galactosidase, such that when produced in *E. coli* hosts carrying the lacZ delta M15 mutation β -galactosidase leads to return of ability to metabolise the chromogenic substrate X-Gal and the production of blue colonies on agar medium supplemented with X-Gal. The insertion of heterologous DNA into the cloning sites of the expression cassette results in the inactivation of lacZ' and thus cells transformed with recombinant plasmid therefore produce colourless colonies on agar medium supplemented with X-Gal (Vieria and Messing, 1982).

The cassette is designed such that heterologous genes to be expressed are cloned using the SspI site and one of the recognition sites from within the polylinker. The SspI site (see list of sites in SEQ ID No 1 and 2 above) is located some 106 nucleotides 5' to the translational start of lacZ' and displacement of the DNA normally found between SspI and the polylinker within lacZ' results in recombinant plasmids which no longer confer a blue colouration on cells in the presence of X-Gal.

In the case of the PGK::REP2 promoter the ATA of the hexanucleotide sequence AATATT equates to the ATG start of the REP2 structural gene. In the case of the control expression cassette, the same triplet corresponds to the ATG start of the PGK structural gene. In both cases, when the cassettes are digested with SspI, the DNA is cleaved between the AT and A of the ATA triplet and a blunt-end is generated.

A DNA fragment carrying the gene to be expressed is then modified such that the first nucleotide of its blunt-ended, 5'-end is the "G" of the translational start codon of the structural gene. The 3'-end of this fragment may have any cohesive end compatible with those that can be generated by cleavage at the hexanucleotide recognition sites within lacZ'. Subsequent fusion of the 5' "G" nucleotide of the heterologous gene to the "AT" blunt-end of the cassette generated by SspI cleavage creates an ATG which is synonymous with both the translational start the heterologous gene and that of the structural genes from which the promoter elements were derived, i.e., PGK in the case of the control cassette and REP2 in the case of the hybrid promoter.

The net result of the utilisation of this cloning strategy is that no changes are made to the nucleotides within the 5' untranslated region of the resultant mRNA, nor are any changes made to the codons of the gene being expressed. This would certainly not be true if a heterologous gene was merely inserted into the sites located solely in the polylinker region.

The method of choice used to allow the isolation of the heterologous gene as a blunt-ended fragment lacking the first two nucleotides of the translational start codon involves creating a recognition site for the restriction enzyme PstI at the start of the gene such that the terminal "G" of the created hexanucleotide sequence CTGCAG corresponds to the "G" of the genes translational start. The site created in the gene need not be PstI, but any site conforming to the consensus CNNNG (where "N" is equivalent to, any nucleotide) which is cleaved by a restriction enzyme immediately before the "G" nucleotide to give a DNA terminus with a 3' overhang, i.e., 3'-NNNN. Similarly, the recognition site used in the expression cassette need not be solely restricted to that of SspI, but can be any restriction site conforming to the consensus NATTAN (where "N" is equivalent to any nucleotide) which can be cleaved by a restriction enzyme between the two "T" nucleotides to give a blunt-end.

One potential problem with this cloning strategy occurs if the heterologous gene contains an internal PstI site. Two possible solutions are, firstly that the gene be inserted in a "two-step"

cloning strategy utilising another internal site 5' to the problem PstI site. Secondly, an oligonucleotide can be designed such that its 5' end corresponds to the G residue of the ATG translational start point. If this oligonucleotide is used in a PCR catalysed reaction to isolate the gene of interest, then cleavage with PstI is unnecessary. However, the original "PstI" strategy is preferable to this latter strategy, since PCR products have frequently been shown to have slightly heterogeneous termini (Hemsley et al., 1989).

Example 2: Preparation of Expression Vectors: A new series of vector backbones were constructed (see below) essentially being replication regions from the *E. coli* plasmid ColE1 and the yeast 2 μ plasmid. For selection in *E. coli* they carried either the bacterial cat or bla gene, conferring resistance to chloramphenicol (Cm) and ampicillin (Amp), respectively. The markers allowing selection in *S. cerevisiae* were either the LEU2 or URA3 gene, which convert appropriately deficient host strains to prototrophy. In the latter case, two alleles were constructed. Plasmids are shown in Fig 4.

Regardless of the nature of the selectable marker, of bacterial or yeast origin, every vector contains a unique SspI site between the bacterial selectable marker and the 2 μ replication origin. It was into this site that the expression cassette and control cassette were inserted. The former was isolated as a 1.6 kb XmnI/SspI fragment, and the latter as a 1.75 kb EcoRI/ SphI fragment. Both DNA fragments were blunt-ended by treatment with T4 DNA polymerase prior to their insertion into the SspI site. The orientation of insertion was such that lacZ' was counter transcribed relative to bla or cat.

Vector characteristics: CRM = chloramphenicol resistance marker. Gene markers transcribe away from STB but can transcribe toward it.

pMTL 8110: CRM, leu-dj gene marker, no cassette.

pMTL 8120: CRM, a defective *S. cerevisiae* URA3 gene and no cassette.

pMTL 8130: CRM, ura3-dj gene marker and no cassette.

pMTL 8131: CRM, ura3-dj gene marker and a cassette driven by the PGK promoter.

pMTL 8133: CRM, a defective *S. cerevisiae* URA3 gene and an expression cassette driven by the PGK:REP2 promoter.

pMTL 8140: CRM, leu2-dj gene marker and no cassette.

The vectors contain a minimum of 19 unique cloning sites in addition to the unique SspI sites. Non-unique sites are given in Table 2.

Evaluation of the Expression Cassettes: The capabilities of the expression system were initially assessed using the neo gene of the transposon Tn903. It encodes aminoglycoside-3'-phosphotransferase type I (APH1), which confers resistance to the antibiotic kanamycin and its analogue G418 (Haas and Dowding, 1975). The gene was available as a "Genblock (1.5 kb EcoRI fragment) from Pharmacia. This fragment was inserted into the EcoRI site of plasmid pUC8 to give plasmid pGENBLOCK. PCR was used to amplify a 1.11 kb fragment carrying the entire structural gene. During PCR the design of the oligonucleotide employed as the primer to the 5' end of the gene was such that a PstI recognition site was created. Specifically, the CAG of the created hexanucleotide sequence CTGCAG replaced the neo translational start codon.

The amplified fragment was digested with PstI and the overhanging 3' ends were removed by utilising the 3' to 5' exonuclease activity of T4 DNA polymerase. The fragment was then ligated with the pMTL 8111 and pMTL8113 expression vectors which had previously been digested with SspI and StuI and dephosphorylated. Colourless transformants were screened for the presence of the neo insert and the correct orientation by restriction analysis, and the plasmids obtained designated pKAN8111 and pKAN8113, respectively. Cells of *S.cerevisiae* strain AS33 carrying either plasmid were shown to be resistant to G418 at levels up to 3 mg/ml, indicative of extremely efficient expression of the neo gene. In contrast, only *E. coli* cells containing pKAN8113 were able to grow in the presence of G418 (at levels greater than 1 mg/ml). Lysates prepared from yeast carrying either plasmid cells were subjected to SDS-PAGE and the Comassie stained electrophoretograms scanned with a Joyce-Loebell laser densitometer. A protein band equating to a size of 30,000 daltons was estimated to represent some 5% of the cell's soluble protein.

Primer Extension Analysis of *S. cerevisiae* mRNA: In order to ascertain the site(s) of transcriptional initiation within the two fusion promoters, mRNA was isolated from exponentially growing YEPD cultures of *S.cerevisiae* AS33 containing pKAN8111 and pKAN8113. A 25

bp oligonucleotide primer was synthesised, complementary to the coding strand at +53 to +77 within the neo coding region, and purified to homogeneity. It was not necessary to consider wild-type chromosomal transcription, since the neo gene does not occur chromosomally. Primer extension was performed and the products compared with end-labelled DNA sequence reactions primed with the same oligo-nucleotide primer.

The results demonstrated that the mRNA transcriptional start point (tsp) of the PGK promoter of pKAN8111 maps to nucleotide at -42. This is one nucleotide further from the AUG than that reported by Van den Heuvel et al. (1989) and 2 nucleotides further than that determined by Mellor et al. (1985). Over 90% of transcription from the PGK:REP2 promoter of pKAN8113 appeared to initiate at nt -87 at a G residue. Thus, REP2 promoter tsp site plays no role in transcription, rather factors within the PGK portion of the promoter direct the position and pattern of RNA initiation. Rathjen and Mellor (1990) have shown that initiation in PGK is reliant on two cis-acting sequences, the TATA element at nt -152 and a sequence, 5'-ACAGATCA-3', located immediately 5' to the site of RNA called the "determinator". In the PGK:REP2 promoter, however, the first "C" of the determinant has been deleted without any apparent effect.

Over Production of PAL in E. coli and S. cerevisiae: A PstI site was introduced over the authentic translational start point of a PAL cDNA clone from *Rhodospiridium toruloides* (Anson et al., 1986; Anson et al., 1987; Rasmussen and Orum, 1991) using PCR-mediated SDM (Higuchi et al., 1988); an XbaI site lying 115 bp downstream from the PAL UAG termination codon. The PAL gene was excised as a PstI (blunt)/XbaI fragment and cloned into SspI/XbaI cut pMTL 8131 and pMTL 8133 to generate pPAL 8131 and pPAL 8133 respectively. The expression of PAL in *S. cerevisiae* strain AS33 is shown in Table 3. The lower expression levels obtained when cells are grown in rich selective media probably reflect a drop in plasmid copy number (Rose and Broach, 1990), although a decline in promoter activity and/or increase in mRNA turnover cannot be discounted.

The crude cell-free extracts were analysed by PAGE (Fig 5) and a band corresponding to a protein of approximate MW 75kD, which is present

only in the strain carrying pPAL 8133, was detected. This corresponds to the molecular weight of the PAL monomer. The gel was scanned with a laser densitometer (Joyce-Loebell) which calculated that this band constitutes approximately 9% of total soluble cell protein. This correlates well with the figure obtained by comparing the specific activity of purified PAL at 30°C with the assay data. This would indicate that the vast majority of the recombinant PAL is produced in an active form.

PAL expression levels in *E.coli* TG1 (Table 3) confirmed the finding that the PGK:REP2 promoter is highly active in *E.coli*, whilst the native PGK promoter is inactive. Deletion of part of the putative "-35" region resulted in partial loss of activity of this promoter in *E.coli* (data not shown), indicating that it is indeed these signals which are activating transcription in *E.coli*. Quantitative scanning of polyacrylamide gels indicated PAL expression levels to be of the order of 10% total soluble cell protein.

MATERIALS AND METHODS: A.1 Strains, Plasmids, Transformation and Media.

The *S.cerevisiae* strain AS33 (a, his3-11, his3-15, leu2-3, leu2-112, ura3-251, ura3-373, trp1) was used throughout. Yeast were transformed by electroporation (Becker and Guarente, 1991) and transformants selected by their ability to complement the appropriate auxotrophic allele. *E.coli* strain TG1 (Carter et al., 1985) was used as host for all DNA manipulations and bacterial expression studies. Plasmid pVT100-U (Vernet et al., 1987) was a kind gift from Dr. T. Vernet and plasmid pCM4 (Close and Rodriguez, 1982) obtained from Pharmacia. All DNA manipulations were carried out essentially as described in Sambrook et al. (1989). Polymerase chain reaction (PCR) was carried out on a programmable thermal cycler using Taq DNA polymerase (Amplitaq, Perkin-Elmer Cetus). DNA sequencing was based on the modified chain termination procedure described by Tabor and Richardson (1987). Oligos were synthesised using an Applied Biosystems 380A DNA synthesiser.

Site-directed mutagenesis (SDM) was performed by a number of techniques. Initially, mutants were created using a derivation of the method described by Carter et al., (1985). Subsequently, SDM was

performed by a method based on that described by Kunkel (1985).

Latter mutagenesis experiments were carried out using a novel coupled-primer method for 'SDM'. Essentially, a PCR product was generated using kinased oligos, one of which contained the mutagenic mis-match, whilst the other was located at a point on the target plasmid such that a restriction site, which was unique in the plasmid, lay between the two primers. This PCR product was mixed with an equimolar amount of target plasmid DNA, which had been passaged through an *E.coli* dut ung strain, and linearised at the unique restriction site. The DNA mixture was denatured at 65°C for 5 min in denaturing buffer (0.2 M NaOH, 0.2 mM EDTA), before neutralisation (2 M NH₄Ac, pH 4.5) and subsequent ethanol precipitation. The DNA was redissolved in annealing buffer (20 mM Tris-HCl, pH 7.4; 2 mM MgCl₂, 50 mM NaCl) and annealed for 15 min at 37°C. Extension reactions were at 37°C for 1 hr in a buffer containing 1x TM buffer, 5 mM DTT, 500 µM dNTPs, 250 µM rATP, 2 units T4 DNA ligase and 10 units Sequenase. Aliquots of this reaction were then transformed into *E.coli* TG1.

Typical mutagenesis frequencies were in the region of 30%. This technique obviates the need for sub-cloning into specialised vectors or the use of repair-deficient strains. Assay for PAL Activity: PAL levels in cell-free extracts were assayed by the method of Abell and Shen (1987). The production of cinnamic acid can be monitored spectrophotometrically at 290 nm. 0.67 ml distilled water, 0.17 ml 6x assay buffer (500 mM Tris-HCl pH 8.5) and 0.17 ml L-phenylalanine (50 mM in 100 mM Tris-HCl pH 8.5) were combined in a 1 ml cuvette (Hughes and Hughes Ltd., UV range). The cuvette and its contents were pre-warmed to 30°C and placed in a Perkin-Elmer Lambda 2 Spectrophotometer. 25 µl of crude cell extract was added and the absorbance at 290 nm was monitored for 30 seconds at 30°C.

One unit of enzyme was defined as the amount catalysing formation of 1 µmol cinnamic acid per minute under the assay conditions used. The molar absorption coefficient for cinnamate at 290 nm, 30°C, pH 8.5 (E_{290}) was taken as 9×10^3 litre/mol/cm (Abell and Shen, 1987). The level of PAL activity can then be calculated as follows:

$$\text{IU/ml} = \frac{\text{deltaA}_{290} \times 10^3 \times \text{Dilution Factor}}{\text{E}_{290} \times \mu\text{l of sample} \times 1000}$$

Protein concentrations were determined by the method of Bradford (1976).

Derivation of the Expression Cassette: The initial stages involved in construction were common to each cassette. Two mutagenic oligonucleotides were employed to PCR amplify a 410 bp fragment of pMTL23 encompassing lacZ' and the lac po region (Chambers et al., 1988). The resultant modified fragment possessed a SspI site at position -106 (relative to the lacZ' translational start codon) and a HpaI site at nucleotide position +293 (relative to the lacZ' start codon). The transcriptional termination signals of the PGK were cloned from *S. cerevisiae* strain LL20 chromosomal DNA as a 373 bp BglIII/ HindIII fragment into M13mtl20 (Chambers et al., 1988). The restriction enzyme recognition sites for ClaI and SspI were eliminated by SDM, and the DNA reisolated as a BglIII/ HindIII fragment. The 3' end of the ADH1 locus was sub-cloned from pVT100-U (Vernet et al., 1987) as a 335 bp SphI/HindIII fragment into similarly cleaved M13mp18. An AccI recognition site removed by SDM, and the region carrying the desired transcriptional termination signals reisolated as a 206 bp HincIII/SphI fragment. The three DNA fragments specifying lacZ', the PGK transcriptional terminator and the ADH1 transcriptional terminator were then fused, by ligation with DNA ligase, in the order and orientation shown in SEQ ID No 1 and 2. Prior to fusion, the staggered ends of the DNA fragment encompassing the PGK transcriptional terminator (those generated by cleavage with BglIII and HindIII) were blunt-ended by treatment with T4 DNA polymerase.

To complete the control cassette, a 3.1 kb HindIII fragment carrying the PGK gene of *S. cerevisiae* strain LL20 was inserted into M13mp8 and SDM employed to create restriction recognition sites for EcoRI and SspI. In the case of the SspI recognition site, its position was such that the ATG triplet corresponding to the translational start codon of the PGK structural gene became the ATA of the SspI site, AATATT. A 766 bp fragment encompassing the transcriptional signals of PGK was then isolated from the resultant mutagenic M13 clone, M13PGK-J, following cleavage with EcoRI and SspI, and ligated to the

999 bp SspI/ SphI fragment composed of lacZ':::PGK::ADH1, such that the SspI recognition site was retained.

To complete the expression cassette containing the hybrid promoter, a 1.8 kb HindIII fragment (nucleotides 4621 to 92 of the sequence of Hartley and Donelson, 1980) carrying the promoter of the 2 μ m plasmid REP2 gene was subcloned into the equivalent site of M13mp8. Recognition sites for the restriction enzymes AccI and SspI were then created in the sequence by SDM. This was achieved by changing the hexanucleotide sequences GTTGTT and AATGGA (respective nucleotide positions 5288 to 5283 and 5199 to 5194; Hartley and Donelson, 1980) to GTCGAC and AATATT, respectively. Additionally, two "G" nucleotides (positions 557 and 580 in SEQ ID No 2) were both changed to "T". The recombinant plasmid obtained was designated M13REP2-J. An additional recognition site for the restriction enzyme ClaI was also created within the PGK derived region of M13PGK-J. The changes made are detailed above in the section on features of SEQ ID No 2, at positions 725 and 727. The transcriptional signals of PGK were then isolated as a 540 bp XmnI/ ClaI fragment, and ligated to a 90 bp AccI/ SspI fragment isolated from M13REP2-J, such that fusion occurred between the compatible ClaI and AccI derived DNA sticky ends. The resultant 630 bp fragment was then ligated to the 999 kb SspI/ SphI fragment composed of lacZ':::PGK::ADH1, such that the SspI recognition site was retained.

Nucleotide sequence analysis of the various components of the constructed cassettes indicated the presence of nucleotide differences to previously published sequences, presumably a consequence of strain variation. Specifically, several base differences were observed between the transcriptional initiation and termination regions of the PGK gene used here and that determined by Hitzeman et al. (1982). By reference to SEQ ID No 2, the Hitzeman et al. (1982) sequence has 5 "A" nucleotides rather than the 4 beginning at position 760, lacks the "G" at position 729, has an extra "A" between nucleotides 1399 and 1400, and an extra "T" nucleotides between position 1493 and 1494. Similarly, the "A" nucleotide at position 1663 was found to be a "G" in the ADH1 gene determined by Bennetzen and Hall (1985).

Two additional nucleotide mutations occurred during the construction

of the expression cassette containing the hybrid promoter, around the junction point between the PGK promoter and the REP2 leader region. Thus, a "C" nucleotide base has been deleted from between positions 538 and 539 in SEQ ID No 1 (the "C" at position 716 in SEQ ID No 2), and the nucleotide base at position 543 has become an "A", rather than the "C" found in the equivalent position of the strain LL20 PGK promoter (position 721 of SEQ ID No 2).

Example 3: Derivation of E. coli/ S. cerevisiae Shuttle Vectors:

Provision of E. coli maintenance and replication functions: the first stage in the construction of the new E. coli/S. cerevisiae vectors was to combine the replicative functions of an E. coli plasmid with that of a S. cerevisiae plasmid. Two basic vectors were made, pMTL8000 and pMTL8100. As shown in Figure 6, both were constructed by isolating a 1.4 kb RsaI, which encompassed the origin of replication and STB locus of the 2 μ plasmid, from plasmid pVT100-U (Vernet et al., 1987), and inserting it into the unique EcoRV sites of either pMTLJ or pMTLCJ to give pMTL8000 or pMTL8100, respectively.

Plasmid pMTLJ was derived from pMTL4 (Chambers et al., 1988), by eliminating the recognition site for the restriction enzyme SspI using the plasmid SDM method. The steps involved in the derivation of pMTLCJ are shown in Figure 7. Essentially, a 0.8 kb BamHI fragment, encoding cat, was excised from plasmid pCM4 (Close and Rodriguez, 1982) and inserted into the BamHI site of M13mp8. The ssDNA prepared from the resultant recombinant was then used as a template in successive SDM experiments to eliminate restriction enzyme recognition sites for EcoRI, NcoI and SspI from the cat structural gene. ds DNA of the mutated M13 recombinant was then prepared, the modified cat gene excised as a 0.8 kb BamHI fragment, blunt-ended by treatment with DNA polymerase I Klenow fragment and ligated to a 1.1 kb SspI/DraI fragment encompassing the replication region of plasmid pMTL4 to give pMTLCJ.

The nucleotide sequences of pMTL8000 and pMTL8100 are shown as SEQ ID No 3 and 4. The 2 μ replication region resides between nucleotides 3154 to 3376 of pMTL8000 and 3003 to 3225 of pMTL8100. The STB locus is between nucleotides 2526 to 2817 of pMTL8000 and between 2375 and 2666 of pMTL8100. The bla structural gene begins at nucleotide 444 of

pMTL8000 and ends at position 1304. The cat structural gene of pMTL8100 begins at nucleotide 461 and ends at position 1117. In both cases, the amino acid sequence of the encoded proteins are shown below the first nucleotide of the corresponding codon in the single letter code. The ColE1 origin of replication lies at nucleotides 2063-2068 and 1912-1917 in pMTL8000 and pMTL8100, respectively.

Provision of markers for plasmid selection in *S. cerevisiae*: The basic backbone of the vector series was completed by inserting DNA sequence elements into pMTL8000 and pMTL8100 which allowed direct selection of the described plasmid series in appropriate auxotrophic *S. cerevisiae* host strains. Two different selective markers were employed.

Firstly, a 1.17 kb BglII fragment containing the *S. cerevisiae* URA3 gene was sub-cloned from pVT100-U into the BamHI site of M13mp8. The ssDNA prepared from the resultant recombinant was then used as a template in successive SDM experiments designed to eliminate unique restriction enzyme recognition sites for NdeI, NcoI, and StuI, and two AccI restriction sites. This modified gene was designated the URA3-J allele. The complete sequence of the DNA fragment actually inserted into the eventual expression vectors (see below) is shown as SEQ ID No 5. The URA3 structural gene initiates at nucleotide 234 and terminates at nucleotide 1034. The amino acid sequence of the encoded protein is shown in the single letter code below the first nucleotide of the corresponding codon.

In addition to the standard URA3 selectable marker, a promoterless version, ura3-d was also created. SDM was employed to create a HpaI site at nt -47 (relative to the AUG start codon) in the URA3-J allele. This equates to changing the "C" nucleotide at position 189 to a "G". Subsequent excision of the gene by cleaving with HpaI at this point removes all sequences necessary for activation of the URA3 gene (Roy et al., 1990), whilst retaining the major transcriptional start points at nt -38 and -33 (Rose and Botstein, 1983). It was anticipated that plasmids endowed with ura3-d would possess elevated plasmid copy number under selective conditions, as observed with plasmids carrying an equivalent promoterless LEU2 gene, leu2-d (Echhart and Hollenberg, 1983).

The second selectable marker used was the LEU2 gene. This was sub-cloned as a 1.46 kb SspI fragment from pMA300 (Montiel et al., 1984) into the SmaI site of pUC8. This fragment lacks the sequences mapped as the UAS of LEU2 at -201 to -187 (Tu and Casadaban, 1990), and disrupts the sequence upstream from LEU2 which codes for a putative regulatory peptide (Andreadis et al., 1982). However, it retains the TATA-like AT-rich sequence between bases -118 to -111 that has been proposed as a site for the yeast TATA-binding factor TFIID (Tu and Casadaban, 1990). The recombinant, pUC8-derived plasmid carrying LEU2 was used as a template in SDM experiments to remove the recognition sites for the restriction enzymes ClaI and EcoRI. In the sequence shown as SEQ ID No 5 the URA3 structural gene initiates at nucleotide 234 and terminates at nucleotide 1034. The amino acid sequence of the encoded protein is shown in the single letter code below the first nucleotide of the corresponding codon.

To insert the three alleles URA3-J, ura3-dJ and leu2-dJ into the unique pMTL 8000 and pMTL 8100, each allele was excised from the appropriate plasmid and converted, where necessary, to a blunt-ended DNA fragment. In the case of URA3-J, plasmid pURA3-J was cleaved with AccI (cleaving at a site within the pUC8 polylinker region) and SmaI (cleaving at a SmaI site residing some 79 nucleotides 3' to the translational stop codon of URA3) and the released c. 1.1 kb fragment carrying URA3 treated with T4 DNA polymerase. The exact sequence of the blunt-ended fragment generated is shown in SEQ ID No 5. A c.0.92 kb blunt-ended fragment carrying the ura3-dJ allele was obtained by cleaving plasmid pURA3-dJ with HpaI and SmaI.

The nucleotide sequence of the fragment obtained exactly corresponds to the sequence shown in SEQ ID No 5 between nucleotide 192 and 1115, inclusive. Plasmid pLEU2-dJ was cleaved with EcoRI (at the recognition site within the pUC8 polylinker region) and AccI (at a recognition site located 100 nucleotides 3' to the translational stop of URA3). The exact sequence of the blunt-ended fragment generated is shown in SEQ ID No 6.

All three isolated fragments carrying URA3-J, ura3-dJ and leu2-dJ were inserted into the unique HpaI site of both pMTL8000 and pMTL8100. With one exception, all the recombinant plasmids obtained no longer

contained HpaI sites. The exceptions were the pMTL8000 and pMTL8100 derivatives carrying ura3-dJ, where the HpaI site is retained at the junction point lying 5' end to the gene. To avoid compromising the segregational stability of the plasmids by potential read-through from the selective markers into STB (Murray and Cesareni, 1986), clones were orientated such that the yeast selective markers transcribed away from the STB locus. For comparative purposes, a plasmid containing the leu2-dJ allele transcribing towards STB were also constructed.

Physical Characterisation of Constructed Vectors: Before proceeding to insert the expression cassette into the vector series, the basic backbone vectors were assessed with regard to their stability (segregational and structural) and copy number.

Measurement of plasmid segregational stability in *S. cerevisiae*: Plasmid segregational stability was estimated using methodology described by Spalding and Tuite (1989). This involved following the loss of a plasmid-encoded phenotypic marker over a number of generations under non-selective conditions. The results are presented in Table 1. All plasmids exhibited a greater degree of segregational stability than that of the well characterised *S.cerevisiae* cloning vector YEp24 (Botstein et al., 1979).

Measurement of structural stability: The structural stability of plasmids in *S. cerevisiae* was assessed by transforming each plasmid into strain AS33, growing cells for approximately 30 generations under selective conditions, and then transferring each plasmid back to *E. coli* by the procedure of Hoffman and Winston (1987). Plasmid DNA was then prepared, by the method of Holmes and Quigley (1981), from the resultant *E. coli* transformants and subjected to restriction enzyme analysis. The restriction patterns obtained with all such plasmids isolated from *E. coli*, using the enzymes SspI and EcoRV, was identical to that of the CsCl-purified DNA originally transformed into strain AS33.

Estimation of plasmid copy number: Plasmid copy number determination was based on the non-isotopic technique of Fitcher and Cox (1984). Approximately 5 µg of total yeast DNA was digested simultaneously with EcoRI and EcoRV. Following agarose gel electrophoresis, a negative

image of the restriction "spectrum" was scanned using a laser densitometer (Joyce-Loebell). The intensity of the band corresponding to plasmid DNA was compared with that of the 2.8 kb rDNA EcoRI fragment. The rDNA was assumed to be present at 140 tandem copies (Philipssen et al., 1991). Plasmid copy number was then calculated as follows:

$$\text{Plasmid Copy Number} = \frac{\text{Area under plasmid peak}}{\text{Area under rDNA 2.8kb peak}} \times \frac{2.8}{\text{plasmid size (kb)}} \times 140$$

Using this method, the copy numbers of the basic plasmid vectors in *S. cerevisiae* were compared to previously characterised high copy number (pMA3a; Spalding and Tuite, 1989) and low copy number (YEp24; Botstein et al., 1979) plasmids. The results in Table 1 confirm that low copy number (pMTL 8120) and high copy number (pMTL 8110, 8130 and 8140) versions, of the vectors described in the present invention, have been constructed.

Table 1 Segregational stability and copy number analysis of the pMTL 81X0 series of vectors.

Plasmid	Cells contg. * Plasmid (%)	Plasmid loss/ cell div(10 ⁻²)	Average copy number/cell
pMTL 8110	84.5	0.842	111
pMTL 8120	77.5	1.174	50
pMTL 8130	82.0	0.992	151
pMTL 8140	85.5	0.783	106
YEp24(URA3)	76.0	1.372	48
pMA3a(leu2-d)	ND	ND	106

* After 20 generations of non-selective exponential growth.

Segregational stability was performed using methodology described by Spalding and Tuite (1989) and is an average of two or more independent experiments. Copy number data is for cells grown in minimal media and is based on the assumption that all cells contain plasmid under these conditions. The selective marker present within each vector is shown in brackets. R = reverse orientation. ND = not determined.

Table 2 Non-unique restriction sites present within the polylinkers of the pMTL 8XXX series of vectors.

Marker	PGK	No Promoter	PGK:REP2
leu2-d	EcoRV.Kpn1.Sst1	EcoRV.Kpn1	EcoRV.Kpn1.Sst1
URA3	EcoRV	EcoRV	EcoRV
ura3-d	EcoRV.Sst1	EcoRV	EcoRV.Sst1
leu2-d	EcoRV.Kpn1.Sst1	EcoRV.Kpn1	EcoRV.Kpn1.Sst1

Table 3 Expression of PAL in *S.cerevisiae* AS33 and *E.coli* TG1. Figures refer to units $\times 10^{-2}$ /mg soluble protein. At least three separate assays were performed for each sample and the maximum error range is indicated. ND = not determined. PAL = presence of PAL gene.

Strain and growth phase	pMTL 8130	pPAL 8133	pPAL 8131
<i>S.cerevis</i> 'AS33 Minimal media Stationary	0	35.5 ± 2	18.1 ± 2
<i>S.cerevis</i> 'AS33 YEPD Early exponent'	0	37.8 ± 3	ND
<i>S.cerevis</i> 'AS33 YEPD Stationary	0	16.5 ± 1	8.5 ± 0.7
<i>E.coli</i> TG1 2xYT Stationary	0	35.2 ± 2	0

REFERENCES:

- Abell, C., and Shen, R. (1987). Meth. Enzymol. 142, 242-248.
- Andreadis, A. et al (1984). J. Biol. Chem. 259, 8059-8062.
- Anson, J., Gilbert, H., Oram, J., and Minton, N. (1986). GB App 8621626
- Anson, J., Gilbert, H., Oram, J., and Minton, N. (1987). Gene 58, 189-199.
- Baim, S., and Sherman, F. (1988). Mol. Cell. Biol. 8, 1591-1601.
- Becker, D., and Guarente, L. (1991). Meth. Enzymol. 194, 182-187.
- Bitter, G., and Egan, K. (1984) Gene 32, 263-274.
- Botstein, D. et al (1979) Gene 8, 17-24.
- Bradford, M. (1976). J. Anal. Biochem. 72, 248-254.
- Carter, P. et al (1985). Oligonucleotide site-directed mutagenesis in M13. (Anglian Biotechnology Ltd., Colchester, Essex).
- Chambers, S. et al (1988a). Gene 68, 139-149.
- Chambers, S. et al (1988b). Appl. Micro. and Biotech. 29, 572-578.
- Close, T., and Rodriguez, R. (1982). Gene 20, 305-316.
- Donahue, T., and Cigan, A. (1988). Mol. Cell. Biol. 8, 2955-2963.
- Futcher, A., and Cox, B. (1984). J. Bacteriol. 157, 283-290.
- Haas, M., and Dowding, J. (1975) Meth. Enzymol. 43, 611-628.
- Harley, C., and Reynolds, R. (1987). Nucl. Acids Res. 15, 2343-2361.
- Hartley, J., and Donelson, J. (1980). Nature 286, 860-865.
- Hemsley, A., et al (1989) Nucl. Acids Res. 17, 6545-6551.
- Higuchi, R. et al (1988). Nucl. Acids Res. 16, 7351-7367.
- Hitzeman, R. et al (1982). Nucl. Acids Res. 10, 7791-7808.
- Hoffman, C., and Winston, F. (1987). Gene 57, 267-272.
- Holmes, D., and Quigley, M. (1981). Anal. Biochem. 114, 193-197.
- Kunkel, T. (1985). Proc. Natl. Acad. Sci. USA 82, 488-492.
- Mellor, J. et al (1985). Gene 33, 215-226.
- Montiel, J. et al (1984). Nucl. Acids Res. 12, 1049-1058.
- Murray, J., and Cesareni, G. (1986). EMBO J 5, 3391-3399.
- Ogden, J. et al (1986). Mol. Cell. Biol. 6, 4335-4343.
- Orum, H. and Rasmussen, O. (1992). Appl. Microbiol. Biotechnol. 36, 745-748.
- Rasmussen, O. and Orum, H. (1991). DNA Sequence J. 1, 207-211.
- Ratzkin, B., and Carbon, J. (1977) Proc. Natl. Acad. Sci. USA 74, 487-491.
- Rose, A., and Broach, J. (1990). Meth. Enzymol. 185, 234-279.
- Rose, M., and Botstein, D. (1983). J. Mol. Biol. 170, 883-904.
- Roy, A. et al (1990). Yeast 6 (special issue), 324.
- Sambrook, J. et al (1989). Molecular cloning - a laboratory manual. Second edition. (Cold Spring Harbour Laboratory, Cold Spring Harbour, NY).
- Spalding, A., and Tuite, M. (1989). J. Gen. Microbiol. 135, 1037-1045.
- Struhl, K. (1986). J. Mol. Biol. 191, 221-229.
- Tabor, S., and Richardson, C. (1987). Proc. Natl. Acad. Sci. USA 84, 4767-4771.
- Tu, H., and Casadaban, M. (1990). Nucl. Acids Res. 18, 3923-3931.
- Vernet, T. et al. (1987). Gene 52, 225-233.
- Vieria, J., and Messing, J. (1982). Gene 19, 259-268.

SEQUENCE LISTING

1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: THE PUBLIC HEALTH LABORATORY SERVICE BOARD
(B) STREET: 61 COLINDALE AVENUE
(C) CITY: LONDON
(E) COUNTRY: UNITED KINGDOM (GB)
(F) POSTAL CODE (ZIP): NW9 5DF

(A) NAME: NIGEL PETER MINTON
(B) STREET: 27 MOBERLY ROAD
(C) CITY: SALISBURY
(D) STATE: WILTSHIRE
(E) COUNTRY: UNITED KINGDOM (GB)
(F) POSTAL CODE (ZIP): SP1 3BZ

(A) NAME: JAMES DUNCAN BRUCE FAULKNER
(B) STREET: 14 BISHOPS COURT, JOHN GARNE WAY
(C) CITY: MARSTON, OXFORD
(D) STATE: OXFORDSHIRE
(E) COUNTRY: UNITED KINGDOM (GB)
(F) POSTAL CODE (ZIP): OX3 OTX

(ii) TITLE OF INVENTION: BIFUNCTIONAL EXPRESSION VECTOR

(iii) NUMBER OF SEQUENCES: 6

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release @1.0, Version @1.25 (EP0)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1619 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*

(ix) FEATURE:

(A) NAME/KEY: misc_recomb
(B) LOCATION: 546..547

(ix) FEATURE:

(A) NAME/KEY: misc_recomb

- (B) LOCATION: 635..636
(ix) FEATURE:
 (A) NAME/KEY: misc_recomb
 (B) LOCATION: 1035..1036
(ix) FEATURE:
 (A) NAME/KEY: misc_recomb
 (B) LOCATION: 1411..1412
(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 550..555
(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 574..579
(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 668..673
(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 692..697

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTGTTTC CCTCCTTCTT GAATTGATGT TACCCTCATA AAGCACGTGG CCTCTTATCG 60
AGAAAGAAAT TACCGTCGCT CGTGATTTGT TTGCAAAAAG AACAAACTG AAAAAACCCA 120
GACACGCTCG ACTTCCTGTC TTCCTATTGA TTGCAGCTTC CAATTTCTGC ACACAACAAG 180
GTCCTAGCGA CGGCTCACAG GTTTTGTAAC AAGCAATCGA AGGTTCTGGA ATGGCGGGAA 240
AGGGTTTAGT ACCACATGCT ATGATGCCCA CTGTGATCTC CAGAGCAAAG TTCGTTTCGAT 300
CGTACTGTTA CTCTCTCTCT TTCAAACAGA ATTGTCCGAA TCGTGTGACA ACAACAGCCT 360
GTTCTCACAC ACTCTTTTCT TCTAACCAAG GGGGTGGTTT AGTTTAGTAG AACCTCGTGA 420
AACTTACATT TACATATATA TAAACTTGCA TAAATTGGTC AATGCAAGAA ATACATATTT 480
GGTCTTTTCT AATTCGTAGT TTTTCAAGTT CTTAGATGCT TTCTTTTCT CTTTTTTAAG 540
ATAATCGACT TGACATTTGA TCTGCACAGA TTTTATAATT TAATAAGCAA GAATACATTA 600
TCAAACGAAC AATACTGGTA AAAGAAAACC AAAATATTAG TTAGCTCACT CATTAGGCAC 660
CCCAGGCTTT AACTTTTATG CTTCCGGCTC GTATGTTGTG TGGAATTGTG AGCGGATAAC 720
AATTTACAC AGGAAACAGC TATGACCATG ATTACGCCAA GCTCGCGAGG CCTCGAGATC 780
TATCGATGCA TGCCATGGTA CCCGGGAGCT CGAATTCTAG AAGCTTCTGC AGACGCGTCG 840
ACGTCATATG GATCCGATAT CGCCGGCAAT TCACTGGCCG TCGTTTTACA ACGTCGTGAC 900
TGGGAAAACC CTGGCGTTAC CCAACTTAAT CGCCTTGCAG CACATCCCCC TTTCGCCAGC 960

TGGCGTAATA GCGAAGAGGC CCGCACCAGT CGCCCTTCCC AACAGTTGCG TAGCCTGAAT 1020
 GGCGAATGGC GCGTTGATCT CCCATGTCTC TACTGGTGGT GGTGCTTCTT TGAATTATT 1080
 GGAAGGTAAG GAATTGCCAG GTGTTGCTTT CTTATCCGAA AAGAAATAAA TTGAATTGAA 1140
 TTGAAATCCA TAGATCAATT TTTTCTTTT CTCTTCCCC ATCCTTTACG CTAAAATAAT 1200
 AGTTTATTTT ATTTTTTGAA TATATTTTAT TTATATACGT ATATATAGAC TATTATTTAC 1260
 TTTTAATGAT TATTAAGATT TTTATTAATA AAAAATTCGT CCTCTTTTTT AATGCCTTTT 1320
 ATGCAGTTTT TTTTCCCAT TCGATATTTT TATGTTCTGGG TTCAGCGTAT TTAAAGTTTA 1380
 ATAACGCGAA AATTCTGCGT TCGTTAAAGC TGACACTTCT AAATAAGCGA ATTTCTTATG 1440
 ATTTATGATT TTTATTATTA AATAAGTTAT AAAAAAATA AGTTTATACA AATTTTAAAG 1500
 TGACTCTTAG GTTTTAAAC GAAAATTCTT ATTCTTGAGT AACTCTTTCC TGTAGGTCAG 1560
 GTTGCTTTCT CAGGTATAGC ATGAGGTCGC TCTTATTGAC CACACCTCTA CCGGCATGC 1619

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1754 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 546..547
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 635..636
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 1035..1036
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 1411..1412
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO 2:

GAATTCAACT CAAGACGCAC AGATATTATA ACATCTGCAT AATAGGCATT TGCAAGAATT 60
ACTCGTGAGT AAGGAAAGAG TGAGGAACTA TCGCATACCT GCATTTAAAG ATGCCGATTT 120
GGGCGCGAAT CCTTTATTTT GGCTTCACCC TCATACTATT ATCAGGGCCA GAAAAAGGAA 180
GTGTTTCCCT CCTTCTTGAA TTGATGTTAC CCTCATAAAG CACGTGGCCT CTTATCGAGA 240
AAGAAATTAC CGTCGCTCGT GATTTGTTTG CAAAAAGAAC AAAACTGAAA AAACCCAGAC 300
ACGCTCGACT TCCTGTCTTC CTATTGATTG CAGCTTCCAA TTTCGTCACA CAACAAGGTC 360
CTAGCGACGG CTCACAGGTT TTGTAACAAG CAATCGAAGG TTCTGGAATG GCGGGAAAGG 420
GTTTAGTACC ACATGCTATG ATGCCCCTG TGATCTCCAG AGCAAAGTTC GTTCGATCGT 480
ACTGTTACTC TCTCTCTTC AACAGAATT GTCCGAATCG TGTGACAACA ACAGCCTGTT 540
CTCACACACT CTTTCTTCT AACCAAGGGG GTGGTTTAGT TTAGTAGAAC CTCGTGAAAC 600
TTACATTTAC ATATATATAA ACTTGACATAA ATTGGTCAAT GCAAGAAATA CATATTTGGT 660
CTTTTCTAAT TCGTAGTTTT TCAAGTTCTT AGATGCTTTC TTTTCTCTT TTTTACAGAT 720
CATCAAGGGA AGTAATTATC TACTTTTTAC AACAAATATA AAACAATATT AGTTAGCTCA 780
CTCATTAGGC ACCCCAGGCT TTACACTTTA TGCTTCCGGC TCGTATGTTG TGTGGAATTG 840
TGAGCGGATA ACAATTTTAC ACAGGAAACA GCTATGACCA TGATTACGCC AAGCTCGCGA 900
GGCCTCGAGA TCTATCGATG CATGCCATGG TACCCGGGAG CTCGAATTCT AGAAGCTTCT 960
GCAGACGCGT CGACGTCATA TGGATCCGAT ATCGCCGGCA ATTCACTGGC CGTCGTTTTA 1020
CAACGTCGTG ACTGGGAAAA CCCTGGCGTT ACCCAACTTA ATCGCCTTGC AGCACATCCC 1080
CCTTTCGCCA GCTGGCGTAA TAGCGAAGAG GCCCGCACCG ATCGCCCTTC CCAACAGTTG 1140
CGTAGCCTGA ATGGCGAATG GCGCGTTGAT CTCCCATGTC TCTACTGGTG GTGGTGCTTC 1200
TTTGGAATTA TTGGAAGTA AGGAATTGCC AGGTGTTGCT TTCTTATCCG AAAAGAAATA 1260
AATTGAATTG AATTGAAATC CATAGATCAA TTTTTTCTT TTCTCTTCC CCATCCTTTA 1320
CGCTAAAATA ATAGTTTATT TTATTTTTTG AATATATTTT ATTTATATAC GTATATATAG 1380
ACTATTATTT ACTTTTAATG ATTATTAAGA TTTTATTAA AAAAAAATC GTCCCTCTTT 1440
TTAATGCCTT TTATGCAGTT TTTTTTCCC ATTCGATATT TCTATGTTG GGTTCAGCGT 1500
ATTTTAAGTT TAATAACTCG AAAATTCTGC GTTCGTTAAA GCTGACACTT CTAAATAAGC 1560
GAATTTCTTA TGATTTATGA TTTTATTAT TAAATAAGTT ATAAAAAAA TAAGTTTATA 1620
CAAATTTTAA AGTGACTCTT AGGTTTTAAA ACGAAAATTC TTATCTTGA GTAACCTCTC 1680
TTTCCTGTAG GTCAGGTTGC TTTCTCAGGT ATAGCATGAG GTCGCTCTTA TTGACCACAC 1740
CTCTACCGGC ATGC

2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3400 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 290..291
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 2294..2295

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

AATATTTTAG TAGCTCGTTA CAGTCCGGTG CGTTTTTGGT TTTTGTAAAG TCGTCTTCA 60
GAGCGCTTTT GGTTCCTAAA AGCGCTCTGA AGTTCCTATA CTTTCTAGCT AGAGAATAGG 120
AACTTCGGAA TAGGAACTTC AAAGCGTTTC CGAAAACGAG CGCTTCCGAA AATGCAACGC 180
GAGCTGCGCA CATACAGCTC ACTGTTACAG TCGCACCTAT ATCTGCGTGT TGCCTGTATA 240
TATATATACA TGAGAAGAAC GGCATAGTGC GTGTTTATGC TTAAATGCGT ATCCCCTAAG 300
AGGCCCCGCA GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT 360
TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA TAAATGCTTC 420
ATTACTATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTCGCC CTTATTCCTT 480
TTTTTGCGGC ATTTTGCTT CCTGTTTTTG CTCACCCAGA AACGCTGGTG AAAGTAAAAG 540
ATGCTGAAGA TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA 600
AGATCCTTGA GAGTTTTTCG CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC 660
TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC GGTCGCCGCA 720
TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG CATCTTACGG 780
ATGGCATGAC AGTAAGAGAA TTATGCAGTG CTGCCATAAC CATGAGTGAT AACACTGCGG 840
CCAACCTACT TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA 900
TGGGGGATCA TGTAACTCGC CTTGATCGTT GGAACCGGA GCTGAATGAA GCCATACCAA 960

ACGACGAGCG TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC AAACCTATTAA 1020
CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGGATG GAGGCGGATA 1080
AAGTTGCAGG ACCACTTCTG CGCTCGGCCC TTCCGGCTGG CTGGTTTATT GCTGATAAAT 1140
CTGGAGCCGG TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC 1200
CCTCCCGTAT CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA 1260
GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAAGTGTCA GACCAAGTTT 1320
ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA ATTTAAAAGG ATCTAGGTGA 1380
AGATCCTTTT TGATAATCTC ATGACCAAAA TCCCTTAACG TGAGTTTTTCG TTCCACTGAG 1440
CGTCAGACCC CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA 1500
TCTGCTGCTT GCAAACAAAA AAACCACCGC TACCAGCGGT GGTGTGTTG CCGGATCAAG 1560
AGCTACCAAC TCITTTTCCG AAGGTAAGT GCTTCAGCAG AGCGCAGATA CCAAATACTG 1620
TTCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA CCGCCTACAT 1680
ACCTCGCTCT GCTAATCCTG TTACCAGTGG CTGCTGCCAG TGGCGATAAG TCGTGTCTTA 1740
CCGGGTTGGA CTCAAGACGA TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGG 1800
GTTCTGTCAC ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC 1860
GTGAGCATTG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG TATCCGGTAA 1920
GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAAC GCCTGGTATC 1980
TTTATAGTCC TGTCGGGTTT CGCCACCTCT GACTTGAGCG TCGATTTTTG TGATGCTCGT 2040
CAGGGGGGCG GAGCCTATGG AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT 2100
TTTGCTGGCC TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC 2160
GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGAG CCGAACGACC GAGCGCAGCG 2220
AGTCAGTGAG CGAGGAAGCG GAAGAGCGCT AGCAGCACGC CATAGTGA CTGCGATGCTG 2280
TCGGAATGGA CGATACTTGT TACCCATCAT TGAATTTTGA ACATCCGAAC CTGGGAGTTT 2340
TCCCTGAAAC AGATAGTATA TTTGAACCTG TATAATAATA TATAGTCTAG CGCTTTACGG 2400
AAGACAATGT ATGTATTTTC GTTCCTGGAG AAACCTATTG ATCTATTGCA TAGGTAATCT 2460
TGCACGTCGC ATCCCGGTT CATTTTCTGC GTTTCATCT TGCATTCAA TAGCATATCT 2520
TTGTAAACGA AGCATCTGTG CTTCATTTTG TAGAACAAAA ATGCAACGCG AGAGCGCTAA 2580
TTTTTCAAAC AAAGAATCTG AGTGCAATT TTACAGAACA GAAATGCAAC GCGAAAGCGC 2640
TATTTTACCA ACGAAGAATC TGTGCTTCAT TTTGTAAAA CAAAAATGCA ACGCGAGAGC 2700
GCTAATTTTT CAAACAAAGA ATCTGAGCTG CATTTTTACA GAACAGAAAT GCAACGCGAG 2760

AGCGCTATTT TACCAACAAA GAATCTATAC TTCTTTTTTG TTCTACAAAA ATGCATCCCG 2820
 AGAGCGCTAT TTTTCTAACA AAGCATCTTA GATTACTTTT TTTCTCCTTT GTGCGCTCTA 2880
 TAATGCAGTC TCTTGATAAC TTTTGGCACT GTAGGTCCGT TAAGGTTAGA AGAAGGCTAC 2940
 TTTGGTGTCT ATTTTCTCTT CCATAAAAA AGCCTGACTC CACTTCCCGC GTTTACTGAT 3000
 TACTAGCGAA GCTGCGGGTG CATTTTTTCA AGATAAAGGC ATCCCGATT ATATTCTATA 3060
 CCGATGTGGA TTGCGCATAC TTTGTGAACA GAAAGTGATA GCGTTGATGA TTCTTCATTG 3120
 GTCAGAAAAT TATGAACGGT TTCTTCTATT TTGTCTCTAT ATACTACGTA TAGGAAATGT 3180
 TTACATTTTC GTATTGTTTT CGATTCACTC TATGAATAGT TCTTACTACA ATTTTTTTGT 3240
 CTAAAGAGTA ATACTAGAGA TAAACATAAA AAATGTAGAG GTCGAGTTTA GATGCAAGTT 3300
 CAAGGAGCGA AAGGTGGATG GGTAGTTAT ATAGGGATAT AGCACAGAGA TATATAGCAA 3360
 AGAGATACTT TTGAGCAATG TTTGTGGAAG CGGTATTGCG 3400

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3249 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 290..291
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 426..427
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 1213..1214
- (ix) FEATURE:
 - (A) NAME/KEY: misc_recomb
 - (B) LOCATION: 2143..2144

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

AATATTTTAG TAGCTCGTTA CAGTCCGGTG CGTTTTTGGT TTTTGGAAAG TCGTCTTCA 60
 GAGCGCTTTT GGTTTTCAAA AGCGCTCTGA AGTTCCTATA CTTTCTAGCT AGAGAATAGG 120
 AACTTCGGAA TAGGAACTTC AAAGCGTTTC CGAAAACGAG CGCTTCCGAA AATGCAACGC 180
 GAGCTGCGCA CATAAGCTC ACTGTTACAG TCGCACCTAT ATCTGCGTGT TGCCTGTATA 240

TATATATACA TGAGAAGAAC GGCATAGTGC GTGTTTATGC TTAAATGCGT ATCCCGCAAG 300
AGGCCCCGCA GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT 360
TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA TAAATGCTTC 420
AATAATGATC CACGAGATTT CAGGAGCTAA GGAAGCTAAA ATGGAGAAAA AAATCACTGG 480
ATATACCACC GTTGATATAT CCCAATGGCA TCGTAAAGAA CATTITGAGG CATTTCAGTC 540
AGTTGCTCAA TGTACCTATA ACCAGACCGT TCAGCTGGAT ATTACGGCCT TTTTAAAGAC 600
CGTAAAGAAA AATAAGCACA AGTTTTATCC GGCCTTTATT CACATTCTTG CCCGCCTGAT 660
GAATGCTCAT CCGGAGTTCC GTATGGCAAT GAAAGACGGT GAGCTGGTGA TATGGGATAG 720
TGTTACCCCT TGTTACACCG TTTTCCATGA GCAAACGTAA ACGTTTTTCAT CGCTCTGGAG 780
TGAATACCAC GACGATTTCC GGCAGTTTCT ACACATATAT TCGCAAGATG TGGCGTGTTA 840
CGGTGAAAAC CTGGCCTATT TCCCTAAAGG GTTTATTGAG AATATGTTTT TCGTCTCAGC 900
CAATCCCTGG GTGAGTTTCA CCAGTTTTGA TTAAACGTG GCCAATATGG ACAACTTCTT 960
CGCCCCCGTT TTCACAATGG GCAAGTATTA TACGCAAGGC GACAAGGTGC TGATGCCGCT 1020
GGCGATTGAG GTTCATCATG CCGTTTGTA TGGCTTCCAT GTCGGCAGAA TGCTTAATGA 1080
ATTACAACAG TACTGCGATG AGTGGCAGGG CGGGGCGTAA TTTTTTTAAG GCAGTTATTG 1140
GTGCCCTTAA ACGCCTGGTG CTACGCCTGA ATAAGTGATA ATAAGCGGAT GAATGGCAGA 1200
AATTGCTCGG ATCAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA TGACCAAAAT 1260
CCCTTAACGT GAGTTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA TCAAAGGATC 1320
TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA AACCACCGCT 1380
ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA AGGTAACTGG 1440
CTTCAGCAGA GCGCAGATAC CAAATACTGT TCTTCTAGTG TAGCCGTAGT TAGGCCACCA 1500
CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT TACCAGTGGC 1560
TGCTGCCAGT GCGGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT AGTTACCGGA 1620
TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT TGGAGCGAAC 1680
GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCATTGA GAAAGCGCCA CGCTTCCCGA 1740
AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG AGCGCACGAG 1800
GGAGCTTCCA GGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC GCCACCTCTG 1860
ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA AAAACGCCAG 1920
CAACGCGGCC TTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTTCTTTCC 1980
TGCGTTATCC CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG CTGATACCGC 2040

TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG AAGAGCGCTA 2100
 GCAGCAGCCC ATAGTGACTG GCGATGCTGT CGGAATGGAC GATACTTGTT ACCCATCATT 2160
 GAATTTTGAA CATCCGAACC TGGGAGTTTT CCCTGAAACA GATAGTATAT TTGAACCTGT 2220
 ATAATAATAT ATAGTCTAGC GCTTTACGGA AGACAATGTA TGTATTTTCGG TTCCTGGAGA 2280
 AACTATTGCA TCTATTGCAT AGGTAATCTT GCACGTGCGA TCCCCGGTTC ATTTTCTGCG 2340
 TTTCCATCTT GCACTTCAAT AGCATATCTT TGTTAACGAA GCATCTGTGC TTCATTTTGT 2400
 AGAACAAAAA TGCAACGCGA GAGCGCTAAT TTTTCAAACA AAGAATCTGA GCTGCATTTT 2460
 TACAGAACAG AAATGCAACG CGAAAGCGCT ATTTTACCAA CGAAGAATCT GTGCTTCATT 2520
 TTTGTAAAC AAAAATGCAA CGCGAGAGCG CTAATTTTTC AAACAAAGAA TCTGAGCTGC 2580
 ATTTTACAG AACAGAAATG CAACGCGAGA GCGCTATTTT ACCAACAAAG AATCTATACT 2640
 TCTTTTTTGT TCTACAAAAA TGCATCCCGA GAGCGCTATT TTTCTAACAA AGCATCTTAG 2700
 ATTACTTTTT TTCTCCTTTG TGCGCTCTAT AATGCAGTCT CTTGATAACT TTTTGCCTG 2760
 TAGGTCCGTT AAGGTTAGAA GAAGGCTACT TTGGTGTCTA TTTTCTCTTC CATAAAAAAA 2820
 GCCTGACTTC ACTTCCCGCG TTTACTGATT ACTAGCGAAG CTGCGGGTGC ATTTTTTCAA 2880
 GATAAAGGCA TCCCCGATTA TATTCTATAC CGATGTGGAT TGCGCATACT TTGTGAACAG 2940
 AAAGTGATAG CGTTGATGAT TCTTCATTGG TCAGAAAATT ATGAACGGTT TCTTCTATTT 3000
 TGTCTCTATA TACTACGTAT AGGAAATGTT TACATTTTCG TATTGTTTTT GATTCACTCT 3060
 ATGAATAGTT CTTACTACAA TTTTTTTGTC TAAAGAGTAA TACTAGAGAT AAACATAAAA 3120
 AATGTAGAGG TCGAGTTTAG ATGCAAGTTC AAGGAGCGAA AGGTGGATGG GTAGGTTATA 3180
 TAGGGATATA GCACAGAGAT ATATAGCAAA GAGATACTTT TGAGCAATGT TTGTGGAAGC 3240
 GGTATTCGC 3249

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1115 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TCGACGGATC TGGCTTTTCA ATTCAATTCA TCATTTTTTT TTTATTCTTT TTTTGTATT 60

CGGTTTCCTT GAAATTTTTT TGATTCCGTA ATCTCCGAAC AGAAGGAAGA ACGAAGGAAG 120
 GAGCACGATT TTTGCATGGT ATATATACGG ATATGTAGTG TTGAAGAAAC ATGAAATTGC 180
 CCAGTATTCT TAACCCAACT GCACAGAACA AAAACCGGAA ACGAAGATAA ATCATGTCTGA 240
 AAGCTACATA TAAGGAACGT GCTGCTACTC ATCCTAGTCC TGTTGCTGCC AAGCTATTTA 300
 ATATCATGCA CGAAAAGCAA ACAAACTTGT GTGCTTCATT GGATGTTTCGT ACCACCAAGG 360
 AATTACTGGA GTTAGTTGAA GCATTAGGTC CCAAATTTG TTTACTAAAA ACACATGTGG 420
 ATATCTTGAC TGATTTTTTCG ATGGAGGGCA CAGTTAAGCC GCTAAAGGCA TTATCCGCCA 480
 AGTACAATTT TTTACTCTTC GAAGACAGAA AATTTGCTGA CATTGGTAAT ACAGTCAAAT 540
 TGCAGTACTC TCGGGGTGTC TATAGAATAG CAGAATGGGC AGACATTACG AATGCACACG 600
 GTGTGGTGGG CCCAGGTATT GTTAGCGGTT TGAAGCAGGC GGCAGAAGAA GTAACAAAGG 660
 AACCTAGAGG ACTTTTGATG TTAGCAGAAT TGTCATGCAA GGGCTCCCTA TCTACTGGAG 720
 AATATACTAA GGGTACTGTT GACATTGCGA AGAGCGACAA AGATTTTGTT ATCGGCTTTA 780
 TTGCTCAAAG AGACATGGGT GGAAGAGATG AAGGTTACGA TTGGTTGATT ATGACACCCG 840
 GTGTGGGTTT AGATGACAAG GGAGACGCAT TGGGTCAACA GTATAGAACC GTGGATGATG 900
 TGGTCTCTAC AGGATCTGAC ATTATTATTG TTGGAAGAGG ACTATTTGCA AAGGGAAGGG 960
 ATGCTAAGGT AGAGGGTGAA CGTTACAGAA AAGCAGGCTG GGAAGCATAT TTGAGAAGAT 1020
 GCGGCCAGCA AACTAAAAA ACTGTATTAT AAGTAAATGC ATCTATACTA AACTCACAAA 1080
 TTAGAGCTTC AATTTAATTA TATCAGTTAT TACCC 1115

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1334 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AATTCCTATT ATTTAAGGAC CTATTGTTTT TTCCAATAGG TGGTTAGCAA TCGTCTTACT 60
 TTCTAACTTT TCTTACCTTT TACATTTTCA CAATATATAT ATATATTTCA AGGATATACC 120
 ATTCTAATGT CTGCCCTAT GTCTGCCCTT AAGAAGATCG TCGTTTTGCC AGGTGACCAC 180
 GTTGGTCAAG AAATCACAGC CGAAGCCATT AAGGTTCTTA AAGCTATTTT TGATGTTTCGT 240

TCCAATGTCA AGTTCGATTT CGAAAATCAT TTAATTGGTG GTGCTGCTAT CGACGCTACA 300
GGTGTCCCAC TTCCAGATGA GGCCTGGAA GCCTCCAAGA AGGTTGATGC CGTTTTGTTA 360
GGTGTGTGG GTGGTCTAA ATGGGGTACC GGTAGTGTTA GACCTGAACA AGGTTTACTA 420
AAAATCCGTA AAGAACTTCA ATTGTACGCC AACTTAAGAC CATGTAACCTT TGCATCCGAC 480
TCTCTTTTAG ACTTATCTCC AATCAAGCCA CAATTGCTA AAGGTAAGTGA CTTCGTTGTT 540
GTCAGAGAAT TAGTGGGAGG TATTTACTTT GGTAAGAGAA AGGAAGACGA TGGTGATGGT 600
GTCGCTTGGG ATAGTGAACA ATACACCGTT CCAGAAGTGC AAAGAATCAC AAGAATGGCC 660
GCTTTCATGG CCCTACAACA TGAGCCACCA TTGCCTATTT GGTCTTGA TAAAGCTAAT 720
GTTTTGGCCT CTTCAGATT ATGGAGAAAA ACTGTGGAGG AAACCATCAA GAACGAATTT 780
CCTACATTGA AGGTTCAACA TCAATTGATT GATTCTGCCG CCATGATCCT AGTTAAGAAC 840
CCAACCCACC TAAATGGTAT TATAATCACC AGCAACATGT TTGGTGATAT CATCTCCGAT 900
GAAGCCTCCG TTATCCCAGG TTCCTTGGGT TTGTTGCCAT CTGCGTCCTT GGCCTCTTTG 960
CCAGACAAGA ACACCGCATT TGGTTTGTAC GAACCATGCC ACGGTTCTGC TCCAGATTTG 1020
CCAAAGAATA AGGTTGACCC TATCGCCACT ATCTTGTCTG CTGCAATGAT GTTGAAATTG 1080
TCATTGAACT TGCCTGAAGA AGGTAAGGCC ATTGAAGATG CAGTTAAAAA GGTTTTGGAT 1140
GCAGGTATCA GAACTGGTGA TTTAGGTGGT TCCAACAGTA CCACCGAAGT CGGTGATGCT 1200
GTCGCCGAAG AAGTTAAGAA AATCCTTGCT TAAAAAGATT CTCTTTTTTT ATGATATTTG 1260
TACATAAACT TTATAAATGA AATTCATAAT AGAAACGACA CGAAATTACA AAATGGAATA 1320
TGTTTCATAGG GTAG 1334


CLAIMS.

1. Promoter DNA incorporating a structural gene starting position characterised in that the DNA has a unique SspI restriction site at the structural gene start position.
2. A method for producing a DNA as claimed in claim 1 comprising subjecting promoter DNA to Site-Directed Mutagenesis to create a unique SspI restriction site at the structural gene start position.
3. A method as claimed in claim 2 wherein the position of the created site is such that the triplet sequence, ATG, corresponding to the translational start codon of the structural gene becomes ATA within the SspI recognition site AATATT.
4. A method as claimed in claim 2 or 3 wherein the heterologous gene to be inserted is similarly modified wherein the nucleotide triplet corresponding to the translational start codon is changed to CAG, while the triplet immediately 5' is changed to CTG in order to create a PstI restriction site, CTGCAG.
5. A method as claimed in claim 4 wherein the creation of the PstI, or equivalent site, is performed simultaneously to isolation of the gene by utilising a mutagenic primer in a polymerase chain reaction (PCR) catalysed gene amplification procedure.
6. A method as claimed in claim 4 or 5 wherein the heterologous gene is digested with PstI restriction endonuclease and the 3' overhanging ends removed by the 3' to 5' exo-nucleolytic activity of T⁴ DNA polymerase, the gene then excised using one or more of the restriction enzymes whose sites are present within the polylinker of the vector whereby the first base of the blunt-ended DNA fragment is the third nucleotide, "G", of its first codon and the gene DNA is then ligated into the vector which has been digested previously with SspI and a restriction enzyme compatible with that used to excise the heterologous gene, whereby fusion of the vector promoter region (which ends in "AT") and heterologous gene (which begins in a "G") results in the recreation of the translational start, ATG.

7. Recombinant DNA comprising a yeast promoter sequence characterized in that the leader region of the promoter sequence is replaced with leader sequence of the replication protein 2 (REP2) gene (ORF C) of the yeast 2 μ m plasmid.
8. Recombinant DNA as claimed in claim 7 wherein the yeast promoter derived portion is that of the phosphoglycerate kinase (PGK) promoter.
9. Recombinant DNA as claimed in claim 7 or 8 wherein the upstream activating sequence element and TATA-box are those as found in the PGK promoter.
10. Recombinant DNA as claimed in any one of claims 7 to 9 wherein the UAS element and TATA-box are fused to the 86 nucleotides residing immediately 5' to the 2 μ m plasmid REP2 gene.
11. Recombinant DNA comprising a sequence of bases 1 to 635 of SEQ ID 1.
12. An expression cassette comprising recombinant DNA as claimed in any one of claims 1 and 7 to 11 characterized in that it further includes a copy of the lacZ' gene, containing the multiple cloning sites of pMTL23, preceded by the promoter DNA of any one of claims 7 to 11, and followed by tandemly arranged, yeast gene-derived, transcriptional terminators.
13. An expression cassette comprising a DNA sequence SEQ ID 1.
14. A method for cloning a heterologous gene into an expression cassette as claimed in claim 12 or 13 wherein a primer oligonucleotide for the heterologous gene is designed having its 5' end corresponding to the G residue of the ATG translational start point, and a specific sequence amplification is carried out using the primer oligonucleotide to isolate the heterologous gene ready for insertion into the cassette.
15. An *E. coli* or *S. cerevisiae* shuttle plasmid comprising an expression cassette as claimed in claim 12, or 13 or as provided by a method as described in any one of claims 2 to 6 or 14.

1/9


Fig. 1.



SUBSTITUTE SHEET (RULE 26)


2/9

Fig.2.



3/9


Fig. 3.




SUBSTITUTE SHEET (RULE 26)

4/9

Fig. 4.



5/9

Fig. 5.

SUBSTITUTE SHEET (RULE 26)

6/9






Fig. 6 (cont.)




8/9



SUBSTITUTE SHEET (RULE 26)

9/9

Fig.7(cont.)



SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/67, 15/81	A3	(11) International Publication Number: WO 94/19472 (43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/GB94/00373 (22) International Filing Date: 25 February 1994 (25.02.94) (30) Priority Data: 9303988.1 26 February 1993 (26.02.93) GB (71) Applicant (for all designated States except US): THE PUBLIC HEALTH LABORATORY SERVICE BOARD [GB/GB]; 61 Colindale Avenue, London NW9 5DF (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): MINTON, Nigel, Peter [GB/GB]; 27 Moberly Road, Salisbury, Wiltshire SP1 3BZ (GB). FAULKNER, James, Duncan, Bruce [GB/GB]; 14 Bishops Court, John Garne Way, Marston, Oxford, Oxfordshire OX3 0TX (GB). (74) Agent: LOCKWOOD, Peter, Brian; MOD(PE), DIPR, IPR1b, Room 2002 Empress State Building, Lillie Road, London SW6 1TR (GB).		(81) Designated States: AU, CA, GB, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 24 November 1994 (24.11.94)
(54) Title: BI-FUNCTIONAL EXPRESSION SYSTEM (57) Abstract A novel expression system is provided comprising a DNA sequence containing transcriptional and translational signals that promote the over production of recombinant proteins both in bacterial hosts (e.g., <i>Escherichia coli</i>) and yeasts (e.g., <i>Saccharomyces cerevisiae</i>). The design of the expression system lends itself to a unique strategy which allows heterologous genes to be directly cloned at a position relative to the transcription/translation signals which is optimal for expression. Particularly provided are expression cassettes comprising a sequence of the invention combined with a purpose built series of plasmids wherein the utility and efficiency of the resultant expression vectors can be demonstrated to over produce protein, particularly phenylalanine ammonia lyase (herein abbreviated to PAL), in <i>E. coli</i> and <i>S. cerevisiae</i> to levels hitherto unattainable.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12N15/67 C12N15/81

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 173 280 (BIO TECHNOLOGY GENERAL CORP.) 5 March 1986 See page 11, lines 29-35; Claims 18, 136, 137 ---	1-6
A	DATABASE WPI Week 9137, Derwent Publications Ltd., London, GB; AN 91-269703 'Recombinant DNA for producing mouse prolactin, strain and production of mouse prolactin' & JP,A,3 175 988 (SHIKISHIMA BOSEKI KK) 31 July 1991 see abstract --- -/--	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 August 1994

Date of mailing of the international search report

14-09-1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Germinario, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NUCLEIC ACIDS RESEARCH vol. 15, no. SUPP, 1987, ENGLAND pages 189 - 217 ROBERTS R.J. 'Restriction enzymes and their isoschizomers' See list of restriction sites ---	1-6
A	NATURE vol. 286, 28 August 1980, LONDON pages 860 - 865 J.L. HARTLEY ET AL. 'Nucleotide sequence of the yeast plasmid' cited in the application see Discussion ---	7-13
A	NUCLEIC ACID RESEARCH vol. 10, no. 23, 1982, OXFORD pages 7791 - 7808 R.A. HITZEMAN ET AL. 'The primary structure of the S. cerevisiae gene for 3-phosphoglycerate kinase' cited in the application Abstract ---	7-13
A	GENE vol. 68, 1988, AMSTERDAM pages 139 - 149 S.P. CHAMBERS ET AL. 'The pMTLnic cloning vector...' cited in the application See summary ---	7-13
A	WO,A,84 04757 (KINGSMAN A.J. ET AL) 6 December 1984 See whole document -----	7-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/00373

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1- Claims 1-6 (14,15)
- 2- Claims 7-13 (14,15)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/00373

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0173280	05-03-86	US-A- 4742004	03-05-88
		AU-B- 603331	15-11-90
		AU-A- 4667785	06-03-86
		AU-A- 6019890	08-11-90
		AU-B- 6309994	28-07-94
		DE-A- 3586473	17-09-92
		EP-A- 0483113	29-04-92
		JP-A- 61111693	29-05-86
		US-A- 5143836	01-09-92
		US-A- 5162217	10-11-92
		US-A- 5059529	22-10-91
		US-A- 5147789	15-09-92
		US-A- 5126252	30-06-92
		US-A- 5112744	12-05-92
		US-A- 5081020	14-01-92
		US-A- 5151364	29-09-92
WO-A-8404757	06-12-84	EP-A, B 0144408	19-06-85
		GB-A, B 2150577	03-07-85
		JP-T- 60501441	05-09-85
		US-A- 4898823	06-02-90

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.